Latest Manufacturing News

SPC Global Holdings is transitioning its senior financing from Scottish Pacific to Commonwealth Bank, locking in $154 million in total facilities and expected to save $3 million annually in interest. This move positions the company for accelerated growth both in Australia and abroad.

Austin Engineering reported a robust 22.2% revenue increase in FY25, driven by a strong North American expansion and improved margins in Asia Pacific. Despite some operational challenges in Chile, the company’s underlying profits soared, setting a confident tone for FY26.

SPC Global reports stronger-than-expected FY25 results driven by international growth and synergy gains, while unveiling a new premium beverage division and a major lender transition.

SPC Global Holdings Ltd reported a 40.66% surge in gross revenue to $383 million for FY2025, driven by strategic acquisitions and operational growth. However, the group recorded a net loss of $41.1 million, reflecting restructuring and merger costs.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

Sparc Technologies reveals up to 60% corrosion reduction in graphene-enhanced water-based epoxy coatings, reinforcing its leadership in sustainable protective coatings innovation.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.